Developing drugs for
DEMENTIA
Dementia is a group of neurodegenerative diseases leading to gradual loss of brain function – such as memory, cognition and daily activities. Dementia is one of the largest unmet healthcare challenges of today. Pharmasum Therapeutics is developing a drug representing a unique innovation in a global market, serving an extremely high unmet medical need.
The Most Common Disease of Our Time
Worldwide, around 55 million people have dementia reaching about 150 million cases in 2050 (WHO 2023). Alzheimer’s disease is the most common form of dementia and contribute to 60–70% of cases. This is a progressive disease leading to death within 10 years. Today, significant therapy options are lacking.
Technology
Scientific approach
The drug candidate PST-674 is a proprietary inhibitor of DYRK1A, which is an enzyme involved in several important processes in the brain. An overdose/overactivity of DYRK1A leads to dementia. The inhibition of DYRK1A therefore offers a novel therapeutic approach for treatment of Alzheimer´s disease.
Patients
Clinical Approach
A Global Market
Market segments:
- Alzheimer’s disease
- Parkinson’s disease
- Down syndrome
The value creation of the technology for society and patients is potentially vast. Pharmasum Therapeutics shares hold significant potential for value growth.